(1R,2S)-2-(bromomethyl)-1-phenylcyclopropanecarboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1R,2S)-2-(bromomethyl)-1-phenylcyclopropanecarboxylic acid
• 英文别名: (1R,2S)-2-(bromomethyl)-1-phenylcyclopropane-1-carboxylic acid
• 化学式: C₁₁H₁₁BrO₂
• 分子量: 255.111
• InChiKey: RLTNPEMFZHYQIJ-KOLCDFICSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1R,2S)-2-(bromomethyl)-1-phenylcyclopropanecarboxylic acid 在 吡啶 、 氯化亚砜 、 肼 作用下， 以 乙醚 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 生成 Z-1-phenyl-2-<(acetylamino)methyl>-N,N-diethylcyclopropanecarboxamide
  参考文献：
  名称：

  1-芳基-2-（氨基甲基）环丙烷羧酸衍生物。一系列潜在的抗抑郁药。

  摘要：

  合成了一系列的1-芳基-2-（氨基甲基）环丙烷羧酸衍生物，并将其评估为潜在的抗抑郁药。具有Z构型的化合物由1-芳基-2-氧代-3-氧杂双环[3.1.0]己烷合成，具有E构型的化合物由（E）-1-苯基-2-（羟甲基）环丙烷羧酸合成。在动物试验中对化合物进行了评估，旨在揭示其潜在的抗抑郁活性和不良副作用的存在。几种衍生物比丙咪嗪和地昔帕明更具活性。根据其在抗抑郁药理动物实验中的活性及其潜在的无副作用，选择了1-苯基-1-[（（二乙基氨基）羰基] -2-（氨基甲基）环丙烷盐酸盐，中alcipranan（INN）。进一步的发展。

  DOI：

  10.1021/jm00385a013
• 作为产物：
  描述：

  (1S,5R)-1-苯基-3-氧杂双环[3.1.0]己-2-酮 在 氢溴酸 作用下， 以 溶剂黄146 为溶剂， 反应 2.0h， 以96%的产率得到(1R,2S)-2-(bromomethyl)-1-phenylcyclopropanecarboxylic acid
  参考文献：
  名称：

  1-芳基-2-（氨基甲基）环丙烷羧酸衍生物。一系列潜在的抗抑郁药。

  摘要：

  合成了一系列的1-芳基-2-（氨基甲基）环丙烷羧酸衍生物，并将其评估为潜在的抗抑郁药。具有Z构型的化合物由1-芳基-2-氧代-3-氧杂双环[3.1.0]己烷合成，具有E构型的化合物由（E）-1-苯基-2-（羟甲基）环丙烷羧酸合成。在动物试验中对化合物进行了评估，旨在揭示其潜在的抗抑郁活性和不良副作用的存在。几种衍生物比丙咪嗪和地昔帕明更具活性。根据其在抗抑郁药理动物实验中的活性及其潜在的无副作用，选择了1-苯基-1-[（（二乙基氨基）羰基] -2-（氨基甲基）环丙烷盐酸盐，中alcipranan（INN）。进一步的发展。

  DOI：

  10.1021/jm00385a013

文献信息

• Cyclopropyl compounds as ccr5 antagonists
  申请人：Peckham Poole Jennifer

  公开号：US20060052408A1

  公开（公告）日：2006-03-09

  The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及式（I）的化合物或其药学上可接受的衍生物，用于治疗与CCR5相关的疾病和障碍，例如，用于抑制HIV复制，预防或治疗HIV感染，并用于治疗由此导致的获得性免疫缺陷综合症（AIDS）。
• Casadio; Bonnaud; Mouzin, Bollettino Chimico Farmaceutico, 1978, vol. 117, # 6, p. 331 - 342
  作者：Casadio、Bonnaud、Mouzin、Cousse

  DOI：——

  日期：——
• Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites
  作者：Giuseppe Ronsisvalle、Agostino Marrazzo、Orazio Prezzavento、Lorella Pasquinucci、Barbara Falcucci、Rosanna Di Toro、Santi Spampinato

  DOI：10.1016/s0968-0896(00)00072-9

  日期：2000.6

  A series of 1-phenyl-2-cyclopropylmethylamines structurally related to (+)- and (-)-MPCB were synthesized and their binding affinities for or, oz, opioid and dopamine (D-2) receptors were evaluated. Substitution of the cis-N-normetazocine with different aminic moieties provided compounds with high affinity and selectivity for sigma binding sites with respect to opioid and dopamine (D2) receptors. The observed increase in sigma(2) affinity as compared to the parent(+)-MPCB, supports the idea that the particular stereochemistry of (+)-cis-N-normetazocine affects sigma(1) selectivity but does not affect ol affinity. The (+/-)-cis isomers of methyl 2-[(1-adamantylamino)methyl]-1-phenylcyclopropane-1-carboxylate (18) displayed a higher affinity and selectivity for the ol and sigma(2) receptor subtypes compared to the (+/-)-trans 19. interestingly, the enantiomer (-)-cis 18 displayed a preference for ol receptor subtype whereas the (+)-cis 18 did for sigma(2). These results prompt us to synthesize compounds with modification of nitrogen and carboxyl groups. The compounds obtained showed high affinities and selectivity for sigma sites. Moreover, modifications of carboxyl groups provided compounds with the highest affinities in the series. In particular, compound 25 with reverse-type ester showed a K-i of 0.6 and 4.05 nM for sigma(1) and sigma(2) binding sites, respectively. (C) 2000 Elsevier Science Ltd. All rights reserved.
• Synthesis of (+)- and (−)-cis-2-[(1-adamantylamino)-methyl]-1-phenylcyclopropane derivatives as high affinity probes for σ1 and σ2 binding sites
  作者：Agostino Marrazzo、Orazio Prezzavento、Maria S Pappalardo、Ennio Bousquet、Manuela Iadanza、Victor W Pike、Giuseppe Ronsisvalle

  DOI：10.1016/s0014-827x(01)01170-3

  日期：2002.1

  Selective ligands for either sigma(1) (sigma(1)) or sigma(2) binding sites are potentially useful for gaining a better understanding of the physiological functions of these proteins. Moreover, potent and selective homochiral sigma(1) and sigma(2) binding site ligands represent leads to potential radioligands for tumour imaging with positron emission tomography (PET). On the basis of their structural similarity to previous leads, new (+)- and (-)-cis-2-[(1-adamantylamino)-methyl]-1-phenylcyclopropane derivatives were synthesised and their binding affinities for sigma(1) and sigma(2) binding sites were determined. Each enantiomer showed high affinity for both sigma(1) and sigma(2) binding sites, but only (-)-cis-methyl-2-[1-adamantyl(methyl)amino]methyl}-1-phenylcyclopropane-carboxylate, (-)-4, showed appreciable selectivity for binding to sigma(1) versus sigma(2) sites. The enantiomers of cis-(2-[1-adamantyl(methyl)amino]methyl}-1-phenylcyclopropyl)methanol, 6, expressed the highest affinity for sigma(1) and sigma(2) binding sites. Ligands (-)-4, (+)-6 and (-)-6 might be rapidly labelled in their N-methyl groups by methylation of the N-desmethyl analogues with [C-11]iodomethane to provide prospective radioligands for PET. The N-desmethyl analogues, which are also high affinity ligands, were prepared and shown to undergo satisfactory methylation with iodomethane. (C) 2002 Elsevier Science S.A. All rights reserved.
• BONNAUD B.; COUSSE H.; MOUZIN G.; BRILEY M.; STENGER A.; FAURAN F.; COUZI+, J. MED. CHEM., 30,(1987) N 2, 318-325
  作者：BONNAUD B.、 COUSSE H.、 MOUZIN G.、 BRILEY M.、 STENGER A.、 FAURAN F.、 COUZI+

  DOI：——

  日期：——